Guninaa Pharmaceuticals is a research-driven Indian pharmaceutical company developing, manufacturing and distributing safe, effective medicines — from molecular research and clinical investigation through regulatory clearance and reliable trade-channel supply.
A working pharmaceutical practice is more than its packaging line. We organise our work around nine capabilities that together support a medicine from research bench to dispensing counter.
Each step in our pipeline is gated by quality and regulatory checkpoints — the next stage cannot begin until the previous one is signed off.
We believe a medicine is only as trustworthy as the system that made it — and that trust is earned, batch by batch, audit by audit, year on year.
Guninaa Pharmaceuticals was founded on the conviction that pharmaceutical excellence is built upstream of dispensing. Every therapy that leaves our supply chain has been research-led at origin, formulated under controlled conditions, validated against compendial standards, and surveilled in real-world use through a structured pharmacovigilance programme.
From breakthrough specialty therapies to trusted generics, our intent is constant: enhance patient outcomes, support clinicians with reliably-supplied medicine, and meet regulators with documentation that pre-empts every reasonable question. The company is young by registration; the standards it is built on are not.
For trade onboarding, product information requests, formulary queries or partnership conversations, the fastest route is the company's direct line. Same number for voice and WhatsApp.
Registered in April 2023 at Bareilly, Uttar Pradesh, Guninaa Pharmaceuticals Private Limited operates across the pharmaceutical value chain — research, manufacturing, regulatory affairs and trade-channel distribution.
Our mandate is simple to state and difficult to deliver: produce medicines worthy of the patients who depend on them.
We are a research-driven enterprise developing, manufacturing and supplying high-quality pharmaceutical products. Our work is anchored in scientific rigour and a commitment to regulatory excellence — from early-stage investigation through clinical study, manufacturing, batch-release testing, and onward distribution to the trade channel.
We pursue a balanced portfolio: trusted generics that broaden access and support cost-conscious care alongside specialty therapies that address narrower clinical needs. Across both, we hold to a single standard — that every product leaving our supply chain is supported by documentation a regulator could request without warning.
The company is registered as Guninaa Pharmaceuticals Private Limited at Bareilly, Uttar Pradesh, with statutory profile recorded with the Ministry of Corporate Affairs as below.
| Corporate Identity | Guninaa Pharmaceuticals Private Limited |
| CIN | U47721UP2023PTC181171 |
| Date of Incorporation | 29 April 2023 |
| Registrar | Registrar of Companies, Kanpur |
| Class & Category | Private Limited Company Limited by Shares · Non-government |
| Authorised Capital | ₹ 10,00,000 |
| Paid-up Capital | ₹ 10,00,000 |
| Directors | Mahendra Khatwani Yahna Khatwani |
| GSTIN | 09AAKCG4349P1ZT (state code 09 — Uttar Pradesh) |
| LEI | 335800JIO4CYUCNMVV98 (Legal Entity Identifier) |
| Registered Office | Building No. A, Mohalla Gali Nababan, Bara Bazar, Bareilly, District Bareilly, Uttar Pradesh — 243001 |
Therapeutic-area research, formulation science, bioequivalence work and ethics-board-supervised clinical investigation across phase-appropriate study designs.
cGMP-aligned manufacturing with validated processes, in-process control, environmental monitoring and release-testing on every batch dispatched to trade.
Regulatory dossier management, marketing-authorisation filings, change control and an end-to-end distribution chain — including cold-chain segments where required.
Eight working categories define the company's day-to-day practice. Each operates under its own standard procedures and quality-system documentation; together they trace a single pathway from research bench to dispensing counter.
Foundational science: target identification, formulation development, bioequivalence study and process improvement. The output of this discipline is the evidence file every other stage depends on.
Controlled production of finished dosage forms with validated equipment, environmental control and complete batch documentation. Manufacturing is gated by quality, not the other way around.
A growing catalogue of bioequivalent generics across acute, chronic and lifestyle disease segments. The intent is access without quality compromise — same compendial standard, broader affordability.
Targeted molecules for narrower indications and complex therapeutic categories, supported by clinician-facing materials and trained medical scientific liaison for substantive product discussion.
Phase-appropriate clinical investigation with independent ethics-board oversight, adherence to ICH-GCP, and prospective collection of safety and efficacy data with audit-trail integrity.
Dossier preparation, marketing-authorisation applications, post-approval change control and continuous tracking of evolving pharmacopoeial and statutory expectations across operating geographies.
Independent compendial testing — assay, dissolution, content uniformity, stability and impurity profiling — with batch release gated by a documented certificate of analysis on every dispatch.
Validated transport lanes, controlled warehousing and traceable last-mile delivery into the trade channel. Where products demand temperature control, excursions are logged and investigated.
Verified pharmacies, hospitals and institutional buyers transact with the company on documented credit or pro-forma terms. Onboarding requires valid drug-licence documentation; orders are fulfilled with batch-level traceability.
Practising clinicians, hospital pharmacy committees and formulary leads may request product information files, peer-reviewed references and comparative data through medical liaison — independent of the commercial channel.
Regulators, accreditation auditors and authorised inspectors are received under the company's audit-readiness protocol. Documentation, batch records and quality-system files are made available within statutory timeframes.
Commercial enquiries, partnership requests, clinical questions and statutory correspondence may be directed to the registered office or by phone and WhatsApp on the number below. Same number for both channels.
Building No. A, Mohalla Gali Nababan, Bara Bazar, City & District Bareilly, Uttar Pradesh — 243001, India.
CIN U47721UP2023PTC181171
GSTIN 09AAKCG4349P1ZT
LEI 335800JIO4CYUCNMVV98
Monday to Saturday · 09:30 — 18:30 IST
Closed on Sundays and gazetted public holidays. Out-of-hours pharmacovigilance and audit lines are routed through the WhatsApp number.
Recurrent enquiries from trade partners, clinicians and regulators — answered briefly here. For anything outside this list, the WhatsApp line on +91 89799 79366 is the fastest channel.
How Guninaa Pharmaceuticals Private Limited collects, uses, retains and protects information of trade partners, clinicians and visitors interacting with the company.
This privacy policy describes how Guninaa Pharmaceuticals Private Limited (the Company, we, our) handles personal and business information collected through trade interactions, telephone and WhatsApp correspondence on +91 89799 79366, and any digital channels operated by the Company. It applies to information about authorised contacts of pharmacies, hospitals, institutional buyers, clinicians, regulators and other counterparties.
We collect: (a) identity and contact information such as full name, designation, organisation, business address, telephone, email and statutory identifiers (GSTIN, drug-licence number); (b) commercial information including order history, invoices, payment references and delivery acknowledgements; (c) technical information from electronic communication including device, IP and timestamp metadata where applicable; and (d) pharmacovigilance information voluntarily reported in connection with a suspected adverse drug reaction or product complaint.
Information is processed on the lawful bases of contract performance, statutory obligation under Indian pharmaceutical and tax law, and legitimate business interest in operating a regulated supply chain. Purposes include order fulfilment, invoicing, drug-licence verification, regulatory reporting, pharmacovigilance, audit compliance and protection against fraud or product diversion.
We share information with: (a) statutory and regulatory authorities where disclosure is required by law; (b) authorised distribution, logistics and payment partners strictly to perform a service requested; (c) professional advisers (legal, audit, tax) under appropriate confidentiality obligations. We do not sell personal information.
We retain information for the period required to satisfy the purposes above and to comply with applicable record-keeping obligations under the Companies Act, the GST regime, the Drugs and Cosmetics Act and pharmacovigilance regulations. On expiry of that period, records are securely deleted or anonymised.
We apply administrative, technical and physical safeguards proportionate to the sensitivity of the data, including access control, segregation of duties, encrypted transit for electronic submissions where supported, and incident-response procedures. No transmission method is perfectly secure; we ask counterparties to apply equivalent diligence on their side.
Subject to applicable law, you may request access to, correction of, restriction on, or deletion of personal information we hold about you. Requests may be made to the registered office or to +91 89799 79366. We will respond within statutory timeframes, subject to verification of identity and to any overriding statutory record-keeping obligation.
This policy may be updated from time to time; the effective version is the one published on the Company's website. The policy is governed by Indian law; the courts at Bareilly, Uttar Pradesh have exclusive jurisdiction over any dispute arising in connection with it.
The terms below govern access to and use of the Company's website, communications and trade-channel interactions. By engaging with the Company, the counterparty accepts these terms.
'Company' means Guninaa Pharmaceuticals Private Limited (CIN U47721UP2023PTC181171), having its registered office at Bareilly, Uttar Pradesh. 'Counterparty', 'you' or 'your' means any person or entity engaging with the Company in a commercial or informational capacity. 'Goods' means pharmaceutical products supplied by the Company.
Trade orders may be placed only by entities holding a valid drug licence and other applicable statutory registrations. By placing an order, the counterparty represents that all such registrations are current and that the contact person is authorised to bind the entity. We reserve the right to verify documentation and to decline or discontinue dealings where verification is not satisfied.
An order placed through accepted channels constitutes an offer to purchase. The Company's acceptance occurs on dispatch confirmation; until that point, the Company may decline an order in whole or in part. Prices are exclusive of taxes unless stated; applicable GST is charged on every invoice. The Company may revise prices for future orders without notice.
Payment is due against the terms communicated at order acceptance — pro-forma, on delivery, or on agreed credit. Outstanding amounts beyond the agreed period may attract interest at the rate notified, suspension of further dispatch, and debit-recovery proceedings under applicable law.
Risk in the Goods passes on delivery to the counterparty or to a logistics partner nominated by the counterparty. Title in the Goods remains with the Company until full payment is received. Acceptance is deemed unless a written discrepancy notice is served within the timeframe set out in the Refund & Returns Policy.
The counterparty undertakes to handle, store, dispense and resell the Goods in compliance with the Drugs and Cosmetics Act and applicable rules, including cold-chain requirements where stated. The counterparty shall not tamper with packaging or labelling and shall maintain records sufficient for batch traceability.
All trademarks, brand elements, product literature, dossier excerpts and digital assets remain the exclusive property of the Company or its licensors. Permitted use is strictly for resale and clinical-information purposes; reproduction, adaptation or commercial reuse without prior written consent is prohibited.
Subject to applicable law, the Company's aggregate liability arising out of or in connection with any single order shall not exceed the invoice value of that order. The Company shall not be liable for indirect, incidental, consequential or punitive damages, or for loss of profit, data or business expectation, except where such limitation is excluded by mandatory statute.
Neither party is liable for delay or failure caused by events outside reasonable control — including natural disaster, public-health emergency, regulatory action, transport disruption, labour stoppage or supply-chain failure — provided notice is given and reasonable mitigation undertaken.
These terms are governed by, and shall be construed in accordance with, the laws of India. The courts at Bareilly, Uttar Pradesh have exclusive jurisdiction over any dispute, claim or proceeding arising out of or in connection with these terms or any transaction governed by them.
Pharmaceutical returns are tightly regulated for patient-safety reasons. The terms below describe the limited circumstances under which returns are accepted and how refunds are processed.
As a regulated pharmaceutical supplier, the Company does not accept returns of correctly supplied Goods on grounds of changed buying preference. Returns are limited to the specific scenarios identified below and are subject to verification.
Returns are eligible where: (a) Goods were supplied in error against the confirmed order; (b) Goods were damaged in transit and the damage was recorded on the proof of delivery; (c) Goods were received with a manufacturing defect or short-shelf-life inconsistent with the order; or (d) a regulatory recall has been initiated by the Company or a competent authority.
Discrepancies under heads (a) and (b) above must be notified to the Company within seven (7) calendar days of receipt with photographic evidence and the original delivery acknowledgement. Defects under head (c) must be notified within thirty (30) calendar days of receipt or, where the defect could not reasonably have been detected earlier, within seven (7) days of detection. Recalls under head (d) follow the timelines in the recall notice.
Returned Goods must be: in original primary and secondary packaging; with intact batch and expiry information; not subject to any tampering, decanting or relabelling; and accompanied by the relevant batch reference, invoice number and a signed return-authorisation form issued by the Company.
Cold-chain products will be accepted for return only where temperature integrity throughout the chain can be evidenced by data logger or equivalent record. Cold-chain breach disqualifies a return regardless of physical condition.
Approved returns are credited to the counterparty against future invoices, or refunded to the originating bank account at the Company's discretion, within fourteen (14) working days of acceptance of the returned consignment. GST adjustments are processed through a credit note compliant with applicable tax rules.
Any dispute regarding a return or refund shall be raised in writing to the registered office. Unresolved disputes are subject to the exclusive jurisdiction of the courts at Bareilly, Uttar Pradesh, and governed by Indian law.
How orders accepted by the Company are processed, dispatched, transported and delivered to verified trade partners across India.
The Company dispatches Goods to verified trade addresses across India where the counterparty holds a valid drug licence and where the Company is in a position to serve under prevailing logistics and regulatory conditions. Service to a particular pin code is confirmed at order acceptance.
Confirmed orders are typically picked, packed and dispatched within two (2) to four (4) working days of acceptance, subject to product availability, batch-release status and successful drug-licence verification. Cold-chain consignments may follow a separate dispatch cadence to align with logger initialisation.
Dispatch is undertaken through validated logistics partners selected for pharmaceutical handling capability, and where applicable, cold-chain qualification. Tracking references, where issued by the carrier, are shared with the counterparty's nominated contact at dispatch.
Temperature-sensitive Goods are dispatched in qualified shipper systems with temperature data loggers as required by product label. The counterparty is asked to inspect the logger record on receipt; any temperature excursion must be flagged before unpacking and stocking.
On delivery, the counterparty's representative is required to inspect the consignment for parcel-count and visible damage, and to record any discrepancy on the proof of delivery. Acceptance of the consignment without such notation is treated as acknowledgement of correct delivery for the purposes of the Refund & Returns Policy.
Logistics charges, where applicable, are stated at order acceptance and itemised on the tax invoice. Insurance, where elected, covers transit risk up to the value declared; where insurance is not elected, transit risk passes per the Terms & Conditions.
Where delivery cannot be completed because the consignee is unavailable, refuses receipt, or where the address is unserviceable, the Goods are returned to the Company's nearest hub. Re-dispatch attracts further logistics charges; perishable or short-shelf-life Goods may be quarantined and disposed of in accordance with regulation.
Dispatch and shipping queries are routed through +91 89799 79366 on voice or WhatsApp during published office hours. Unresolved escalations may be addressed in writing to the registered office at Bareilly, Uttar Pradesh.